Brief: Arch Biopartners Engages Global CRO to Conduct LSALT Peptide Phase II Trial For Treatment Of Complications In Covid-19 Patients In U.S.
14/07/2020 12:19
July 14 (Reuters) - Arch Biopartners Inc ARCH.V :
* ARCH BIOPARTNERS ENGAGES GLOBAL CRO TO CONDUCT LSALT
PEPTIDE
(METABLOK) PHASE II TRIAL FOR TREATMENT OF COMPLICATIONS IN
COVID-19 PATIENTS IN THE U.S.
* ARCH BIOPARTNERS - PHASE 1 STUDY IN 52 HEALTHY MALE &
FEMALE
VOLUNTEERS IS COMPLETE WITH LSALT PEPTIDE MEETING PRIMARY
ENDPOINT OF SAFETY, TOLERABILITY
Source text for Eikon: ID:nGNX3p8sLk
Further company coverage: ARCH.V
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Arch Biopartners
See all newsBrief: Arch Biopartners To Expand Phase Ii Cardiac Surgery-Associated Acute Kidney Injury Trial To The US
Brief: Arch Biopartners Closes Non-Brokered Private Placement
Brief: Arch Strengthens Its Position As A Leading Kidney Therapeutics Company With The Acquisition Of A Breakthrough Platform To Develop New Drugs Targeting Chronic Kidney Disease (Ckd)
Brief: Arch Biopartners Closes Non-Brokered Private Placement
Brief: Arch Biopartners Announces Ontario Research Ethics Board Approval To Start Phase II Trial For LSALT Peptide